Lotronex risk management progress
Executive Summary
FDA's Drug Safety & Risk Management Advisory Committee will receive a progress report May 5 on the risk management program for GlaxoSmithKline's Lotronex. The committee is also slated to discuss medication errors relating to the labeling and packaging of drug products in low density polyethylene (LDPE) plastic vials. The meeting will be held at the CDER Advisory Committee conference room, 5630 Fishers Lane in Rockville, Md. beginning at 8 a.m. [To 1watch a webcast of this meeting, go to FDAAdvisoryCommittee.com]...